Managing Mergers With Sail Biomedicines' Guillaume Pfefer, Ph.D.

Business Of Biotech

We love to hear from our listeners. Send us a message.

While you might be aware that Sail Biomedicines was just formed up in Q4 of last year, the product of Flagship Pioneering’s decision to merge Senda Biosciences and Laronde, two of its programmable medicine platform companies. What you likely haven’t heard is the inside story on how the merger was executed, how the two companies are integrating their talent, IP, and resources, and what Sail Biomedicines CEO Dr. Guillaume Pfefer and team are currently doing to take the fruits of the company’s platform into the clinic. On this episode of the Business of Biotech, Dr. Pfefer takes us under the hood of Sail Biomedicines and its mission to marry evolution and AI to develop programmable medicines based on eRNA.

Register for Bioprocess Online’s Bio Expo Live, being held July 30th through August 1st . This inaugural expo is a fantastic opportunity for biopharma companies and contract manufacturers to evaluate the latest and greatest from the comfort of your desktop or mobile device. Conveniently, we’ve broken down the lineup into Upstream Solutions July 30th, Downstream Solutions July 31st, and Quality, Analytical, and Data Solutions August 1st. It’s absolutely free to register for this series of short, digestible, and interactive sessions -- just hit the links above to register for Bio Expo Live today!

Chapters

1. Merger and Ambitions of Cell Biomedicine (00:00:00)

2. Global Perspective Shaping Leadership Style (00:17:14)

3. Immigrant Experience and Embracing Diversity (00:22:33)

4. Endless RNA and Programmable Medicine (00:27:01)

5. Partnerships and Speed in Fully-Programmed Medicine (00:40:28)

6. Biotech Podcast Business Introduction (00:50:04)